The FDA approved Epkinly in combination with other standard lymphoma drugs, rituximab + lenalidomide, for relapsed or ...

Genmab plans to present full results at an upcoming medical meeting.

Researchers sought to determine whether zanubrutinib combined with rituximab and lenalidomide would improve remission rates in older adults with newly diagnosed DLBCL.

Friday afternoon, the company and its partner Genmab shared word that the phase 3 Epcore DLBCL-1 trial missed on its primary endpoint of overall survival. Specifically, the partners' Epkinly failed to ...

Combination of mitoxantrone hydrochloride liposome with cyclophosphamide, vincristine, and prednisone (CMOP) for patients with treatment-naïve peripheral T-cell lymphomas (PTCLs): Extended follow-up ...

Please provide your email address to receive an email when new articles are posted on . In this video, Leo I. Gordon, MD, FACP, discusses highlights from a debate at Lymphoma, Leukemia & Myeloma ...

Epkinly monotherapy significantly improved progression-free survival in relapsed/refractory DLBCL patients, reducing cancer ...

Company Announcement Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...

Recent advancements in treatment options for patients with diffuse large B-cell lymphoma have been practice-changing. He wasn’t expecting a fall during an ice storm to lead to a cancer diagnosis. But ...

AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to ...